Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259706 | 0.88 | MEN1 (0.77) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL682877 | 0.87 | MEN1 (0.71) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL19303149 | 0.86 | KMT2A (0.59) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL8461683 | 0.85 | MEN1 (0.73) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL14363224 | 0.85 | MEN1 (0.73) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL259468 | 0.85 | KCNK3 (0.87) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL29434800 | 0.85 | KCNK3 (0.87) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL2908619 | 0.84 | MEN1 (0.89) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL7893547 | 0.84 | MEN1 (0.67) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 | |
| SCHEMBL21133083 | 0.84 | KCNK3 (0.86) | MEN1KMT2ARXFP1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020031816-A1 | METHOD OF INHIBITION OF HUMAN GLYCOGEN PHOSPHORYLASE | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0978279-A1 | Inhibitors of human glycogen phosphorylase | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| US-5998463-A | Glycogen phosphorylase inhibitors | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | MEN1 4180/4885KMT2A 2831/4885RXFP1 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.